GIK infusion

Related by string. * : GIK / Infusions . InFusion . infusions . INFUSION . Infusion : Colleague infusion pumps . COLLEAGUE infusion pumps . intravenous infusion . resin infusion . Knowledge Infusion . infusion pumps . TARP infusions . infusion . Colleague Volumetric Infusion Pumps . SKYY Infusions . intravenous infusions . herbal infusions . iron sucrose infusion . InFusion SimSci Esscor Triconex * *

Related by context. Frequent words. (Click for all words.) 59 thrombolytic therapy 58 serum uric acid 57 noninferiority 57 STEMI patients 56 myocardial infarctions 56 fondaparinux 56 myocardial infarction stroke 56 cerebrovascular events 55 myocardial infarction MI 55 ticagrelor 55 unfractionated heparin 55 microalbuminuria 55 target vessel revascularization 55 glomerular filtration rate 55 clopidogrel 54 CYPHER ® Stent 54 prespecified 54 nonsignificant 54 coronary revascularization 54 subgroup analyzes 54 virologic response 54 peginterferon 54 infarct size 54 thromboembolic events 54 composite endpoint 54 ADAS cog 54 cardiovascular morbidity 54 hemoglobin concentration 54 LMWH 54 anticoagulation 53 sinus rhythm 53 cardiac dysfunction 53 rehospitalization 53 P = .# 53 multicentre 53 QTc 53 pioglitazone 53 left ventricular dysfunction 53 adalimumab 53 randomisation 53 STEMI 53 carotid artery stenting 53 dronedarone 53 lamotrigine 52 serum sodium 52 myocardial infarction 52 eGFR 52 undergoing coronary artery 52 myocardial ischemia 52 glatiramer acetate 52 TRITON TIMI 52 telmisartan 52 randomized Phase III 52 virologic 52 virologic failure 52 abciximab 52 ischemic stroke 52 bivalirudin 52 lacosamide 52 chemoradiotherapy 52 lipid lowering drugs 52 TAXUS stent 52 LVEF 52 morbidity mortality 52 creatinine clearance 52 Secondary endpoints include 52 candesartan 52 thrombotic events 52 meta analysis 52 ziprasidone 52 serum concentrations 52 active comparator 52 cardiac toxicity 52 carotid intima media 52 postsurgical 51 ANOVA 51 tiotropium 51 cystatin C 51 platelet activation 51 montelukast 51 estimated glomerular filtration 51 IPSS 51 placebo controlled trials 51 mcg dose 51 amlodipine 51 cardiovascular mortality 51 symptom onset 51 cardiovascular hospitalization 51 CMV infection 51 warfarin therapy 51 Secondary endpoints included 51 revascularization 51 hemodynamics 51 thromboembolism 51 statistically significant p = 51 glycated hemoglobin 51 quetiapine 51 infarct 51 nesiritide 50 zoledronic acid 50 laboratory abnormalities

Back to home page